You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.
A federal court ruled this week that IonPath's MIBIscope does not infringe on Fluidigm's technology, though the company has indicated it will likely appeal.
TruGenX claims that Thermo Fisher's technical support did not resolve testing issues for months, damaging its business and reputation.
According to Retraction Watch, Carlo Croce, an Ohio State University cancer researcher, has lost his latest court appeal.
The appellate court's decision deals a blow to a 2017 Columbia University lawsuit that alleged Illumina infringed one of the invalidated patents.
Illumina said it plans to pursue a permanent injunction against BGI in the UK until the four patents expire — three in 2023 and one in 2027.
In their complaint the plaintiffs claimed Illumina fraudulently obtained two US patents by concealing a reference from the patent office.
Despite the havoc wreaked by the COVID-19 pandemic on the economy, several companies in the index saw their shares rise by triple-digit percentages last year.
Ravgen has alleged that several leading NGS-based non-invasive prenatal testing and oncology assays infringe two patents held by the firm.
A man in India is suing the Serum Institute of India, saying that he suffered serious side effects from a vaccine it is testing, but the institute has rejected those claims, the Economic Times reports.
CareDx first sued Natera in March 2019 for infringing two of its patents, then amended the suit a year later to add a third patent.
Politico reports that the NYPD DNA database has grown since it announced it would be removing profiles from it.
Forbes reports that a structural biology lab at Oxford University studying the coronavirus was hacked.
Science reports that a Dutch research funding agency is combating a ransomware attack.
In Science this week: set of 64 haplotype assemblies from 32 individuals, and more.